TABLE 1.
Baseline characteristics of people living with HIV who attended the Target Clinic in 2018–2019, comparing male and female participants.
| Baseline characteristics |
N
|
Male participants |
Female participants |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | Mean | s.d. | n | % | Mean | s.d. | n | % | Mean | s.d. | |
| N | 97 | 100.00 | - | - | 36 | 37.11 | - | - | 61 | 62.88 | - | - |
| Age (years) | - | - | 37.34 | 12.85 | - | - | 35.52 | 13.87 | - | 38.26 | 11.88 | |
| Living area | ||||||||||||
| Rural | 42 | 43.29 | - | - | 18 | 50.00 | - | - | 24 | 39.34 | - | - |
| Urban | 51 | 52.58 | - | - | 17 | 47.22 | - | - | 34 | 55.73 | - | - |
| Unknown | 4 | 4.12 | - | - | 1 | 2.78 | - | - | 3 | 4.91 | - | - |
| Employment status | ||||||||||||
| Employed | 6 | 6.19 | - | - | 4 | 1.11 | - | 2 | 3.28 | - | - | |
| Self-employed | 52 | 53.61 | - | - | 17 | 47.22 | - | - | 35 | 57.38 | - | - |
| Unemployed | 26 | 26.81 | - | - | 10 | 27.78 | - | - | 16 | 26.22 | - | - |
| Unknown | 13 | 13.40 | - | - | 8 | 22.22 | - | - | 5 | 8.20 | - | - |
| Years since diagnosis | - | - | 13.86 | 4.71 | - | - | 13.00 | 5.46 | - | - | 14.22 | 4.41 |
| Years on ART | - | - | 13.18 | 3.92 | - | - | 12.81 | 3.96 | - | - | 13.40 | 3.92 |
| Years on 2LART | - | - | 7.42 | 2.07 | - | - | 7.04 | 2.18 | - | - | 7.66 | 1.96 |
| Types of 2LART regimens | ||||||||||||
| AZT + 3TC + LPV/r | 54 | 55.67 | - | - | 23 | 23.71 | - | - | 31 | 31.96 | - | - |
| AZT + 3TC + ATV/r | 16 | 16.50 | - | - | 5 | 5.15 | - | - | 11 | 11.34 | - | - |
| ABC + 3TC + LPV/r | 7 | 7.22 | - | - | 2 | 2.06 | - | - | 5 | 5.15 | - | - |
| TDF + 3TC + LPV/r | 5 | 5.15 | - | - | 0 | 0.00 | - | - | 5 | 5.15 | - | - |
| TDF + 3TC + ATV/r | 4 | 4.12 | - | - | 1 | 1.03 | - | - | 3 | 3.09 | - | - |
| AZT + DDI + LPV/r | 2 | 2.06 | - | - | 1 | 1.03 | - | - | 1 | 1.03 | - | - |
| AZT + 3TC + LPV/r + TDF | 3 | 3.09 | - | - | 2 | 2.06 | - | - | 1 | 1.03 | - | - |
| ABC + 3TC + ATV/r | 1 | 1.03 | - | - | 0 | 0.00 | - | - | 1 | 1.03 | - | - |
| AZT + 3TC + DTG | 1 | 1.03 | - | - | 1 | 1.03 | - | - | 0 | 0.00 | - | - |
| TDF + FTC + LPV/r | 1 | 1.03 | - | - | 0 | 0.00 | - | - | 1 | 1.03 | - | - |
| TDF + 3TC + DTG | 1 | 1.03 | - | - | 1 | 1.03 | - | - | 0 | 0.00 | - | - |
| TDF + EFV + ATV/r | 1 | 1.03 | - | - | 0 | 0.00 | - | - | 1 | 1.03 | - | - |
| DTG + 3TC + LPV/r | 1 | 1.03 | - | - | 0 | 0.00 | - | - | 1 | 1.03 | - | - |
ABC, Abacavir; ATV/r, Atazanavir/ritonavir; AZT, Zidovudine; D4T, Stavudine; DDI, Didanosine; EFV, Efavirenz; FTC, Emtricitabine; LPV/r, Lopinavir/ritonavir; TDF, Tenofovir; 3TC, Lamivudine.